Table 5.

Multivariate linear regression analyses with percentage changes of bone mineral density over followup period as dependent variables.

Characteristicβ (95% CI)p
Femoral neck
  Transitional menstrual status−0.460 (−1.632, 0.712)0.439
  New organ damage−2.417 (−4.526, −0.308)0.025*
  Antiosteoporosis therapies3.397 (0.797, 5.996)0.011*
Total hip
  Transitional menstrual status−0.526 (−1.570, 0.517)0.319
  Flare during followup−1.262 (−3.662, 1.138)0.300
  New organ damage−1.667 (−3.607, 0.274)0.092
  Daily oral glucocorticoids ≥ 7.5 mg for ≥ 3 mos−0.614 (−3.406, 2.178)0.664
  Cumulative dose of glucocorticoids−0.073 (−0.286, 0.141)0.502
  Antiosteoporosis therapies3.729 (1.389, 6.070)0.002*
Lumbar spine
  Transitional menstrual status−1.808 (−3.259, −0.357)0.015*
  25[OH]D level0.116 (−0.021, 0.254)0.097
  Flare during followup−1.342 (−4.390, 1.584)0.385
  Oral glucocorticoids−6.307 (−14.197, 1.584)0.116
  Cumulative dose of glucocorticoids−0.432 (−0.887, 0.022)0.062
  Cumulative duration of glucocorticoids0.150 (−0.010, 0.310)0.065
  Antiosteoporosis therapies6.048 (2.796, 9.301)< 0.0005*
  • * Statistically significant. 25[OH]D: 25-hydroxy Vitamin D.